Interestingly, it was observed that tumors with KEAP1 and tumors with KEAP1/TP53 were entirely different in terms of mutational repertoire, the degree of intra-tumor heterogeneity, evolutionary trajectories, pathway-level signatures, and immune microenvironment [17]. This evidence concerns the gene TP53 and neoplasm.